FY2026 EPS Estimate for X4 Pharmaceuticals Lifted by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at Brookline Capital Markets upped their FY2026 earnings per share (EPS) estimates for X4 Pharmaceuticals in a report released on Wednesday, November 4th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($0.69) per share for the year, up from their prior forecast of ($0.71). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. Brookline Capital Markets also issued estimates for X4 Pharmaceuticals’ Q4 2026 earnings at ($0.24) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.44) EPS and FY2029 earnings at ($0.17) EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. X4 Pharmaceuticals had a negative return on equity of 47.35% and a negative net margin of 474.74%. The company had revenue of $2.88 million during the quarter, compared to the consensus estimate of $2.78 million.

Separately, Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.25.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock opened at $3.33 on Tuesday. X4 Pharmaceuticals has a 1 year low of $2.43 and a 1 year high of $4.83. The firm has a 50 day moving average price of $3.22 and a 200 day moving average price of $3.78. The company has a debt-to-equity ratio of 0.49, a quick ratio of 11.02 and a current ratio of 11.30.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its stake in shares of X4 Pharmaceuticals by 2,871.0% in the third quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company’s stock worth $618,000 after acquiring an additional 206,080 shares in the last quarter. Alps Advisors Inc. boosted its holdings in X4 Pharmaceuticals by 36.2% in the third quarter. Alps Advisors Inc. now owns 130,424 shares of the company’s stock valued at $378,000 after purchasing an additional 34,698 shares during the last quarter. WINTON GROUP Ltd grew its stake in X4 Pharmaceuticals by 35.8% during the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock valued at $67,000 after purchasing an additional 3,800 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in X4 Pharmaceuticals during the 2nd quarter valued at approximately $313,000. Finally, AXQ Capital LP acquired a new stake in X4 Pharmaceuticals during the 2nd quarter valued at approximately $107,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Insiders Place Their Bets

In other news, President John Volpone sold 24,576 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $109,117.44. Following the completion of the sale, the president owned 265,305 shares in the company, valued at approximately $1,177,954.20. The trade was a 8.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Adam R. Craig sold 47,436 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the sale, the chairman owned 328,651 shares of the company’s stock, valued at $1,459,210.44. The trade was a 12.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 83,779 shares of company stock worth $353,387 over the last three months. 1.13% of the stock is owned by insiders.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.